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Abstract
Background: Over-expression of P-Glycoprotein (Pgp) induces acquired drug resistance. Therefore, targeting Pgp as a dominant 
efflux transporter involved in emergence of multidrug resistance (MDR) has become a major strategy for reversibility of sensitivity to 
chemotherapy. 
Objectives: The aim of this study was to design sgRNAs targeting ABCB1 in order to knockout and inhibit the expression of Pgp in Adriamycin 
resistant (A2780/ADR) ovarian cancer cell line.
Methods: This study was performed as a bioinformatics and computational research in Qazvin University of Medical Sciences in collaboration 
with the Isfahan University of Medical Sciences during 2015-2016. All the 28 exons of the ABCB1 gene were separately investigated in terms of 
single guide RNA (sgRNA) target sites with regards to the highest on-target and lowest off-target activities, using www.deskgen.com website. 
Three sgRNA sequences were chosen and synthesized by the GeneCopoeia company. All the plasmids were validated after extraction using 
BamH1 and EcoR1 restriction enzymes. 
Results: Sequences of the three sgRNAs were selected close to the start codon (ATG) in order to maximize the possibility of exons 4 and 5 
knockout. Digested pCRISPR-CG01, using BamH1 and EcoR1, was electrophorized on 1.5% agarose gel. Detection of the two 330bp and 10100bp 
fragments on the gel confirmed the integrity of the plasmid and success of the restriction enzyme digestion. 
Conclusions: The vectors containing the designed sgRNA sequences and CRISPR associated protein (Cas9) can inhibit Pgp gene expression 
in cell lines over-expressing this gene, including A2780/ADR.
Keywords: Drug Resistance, P-Glycoprotein, Ovarian Cancer, CRISPR
Copyright© 2017, Qazvin University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom-
mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us-
ages, provided the original work is properly cited.
1. Background
Resistance to chemotherapy is a major issue in treat-
ment of ovarian cancer, so that many tumours that ini-
tially respond to treatments, relapse and become resis-
tant to several anticancer agents with various structures 
and mechanisms of action. This phenomenon is known 
as multidrug resistance (MDR) (1,2). Drug resistance can 
be caused by various mechanisms, including changes 
in pharmacokinetics and drug metabolism, changes 
in the expression or function of the drug target (e.g., 
up-regulated expression or replication of the gene, in-
creased expression of β-tubulin isotypes and mutations 
in topoisomerase II), drug degradation in cell organelles, 
changes in the pathways involved in repairing DNA dam-
age caused by the drug, changes in apoptosis signalling 
pathways and expression of the proteins that are directly 
involved in cellular trafficking of the drug (3). One of the 
main mechanisms of drug resistance is the expression 
of efflux transporters of the drug in cancer cells, which 
subsequently reduces the intracellular accumulation of 
chemotherapy agents that leads required administration 
of higher doses of the drug (4).
Many of the drug resistance mechanisms are mediated 
by efflux pumps, such as the members of adenosine tri-
phosphate (ATP)-binding cassette (ABC) transporters 
superfamily (3). Most of the ABC transporters contain 
at least two transmembrane and two nucleotide-bind-
ing domains and their main function is to efflux a wide 
range of drugs and xenobiotics out of the cell (5,6). Ap-
proximately, 48 isoforms of ABC transporters have been 
identified which are categorized into seven subfamilies 
(ABCA-ABCG), based on the homology in their nucleo-
tide-binding domain (6,7). Pgp is one of the most recog-
nized human efflux transporter and is known to be the 
key mediator of resistance to a wide range of anticancer 
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drugs (8). The most common ABC transporter involved in 
MDR is Pgp which has several broad features and identi-
fies hundreds of compounds as small as 300 to 4000 Da. 
Pgp is therefore considered as an important drug efflux 
transporter in cancer studies (9). ABCB1, the Pgp encod-
ing gene, is located on chromosome 7, at q21, and con-
sists of 28 exons which encode a protein of 1280 amino 
acids (6). Pgp consists of 12 cytosolic hydrophobic mem-
brane domains and 2 nucleotide-binding domains. The 
protein is arranged in two homogeneous halves, which 
are joined by a flexible linker region. Each half contains 
6 cytosolic membrane domains and one cytosolic ATP-
binding domain. The cytosolic domains are responsible 
for determining the properties of the substrate, while the 
nucleotide-binding domains are responsible for binding 
to ATP and hydrolysis, leading to the transfer of the sub-
strates (10,11). 
Since a slight up-regulation in Pgp expression in can-
cer cells leads to complete drug resistance, Pgp is known 
as the main efflux transporter which is involved in the 
development of MDR (12). Accordingly, inhibiting Pgp 
activity has been became a major strategy for reversing 
sensitivity to chemotherapy over the past 20 years (12,13). 
Inhibitory strategies include inhibiting drug binding to 
Pgp, inhibiting the activity of Pgp-ATPase, interference 
with its surrounding environment (the lipidic bilayer) 
(14) and knockdown of the Pgp gene expression using 
various techniques, such as microRNAs and RNAi (15).
In the past decade, a new approach has emerged that 
enables researchers to manipulate virtually any gene in a 
wide variety of cells and organisms. This major technolo-
gy, usually called the genome-editing, is based on the ap-
plication of engineered chimeric nucleases that consists 
of sequence-specific DNA-binding domains. Among these 
chimeric nucleases are Zinc-Finger Nucleases (ZFN) and 
Transcription Activator Like Effector Nucleases (TALENs) 
that allow inducing efficient and accurate genetic chang-
es through the induction of a double-strand break (DSB) 
at a specific target sequence followed by stimulation of 
cellular DNA repair pathways, including error-prone 
non-homologous end joining (NHEJ) and the homolo-
gous recombination (HR). CRISPR/Cas systems are the 
most recently discovered member of this set of dedicat-
ed target-specific genomics engineering tools. Although 
each of these three methods of gene modification has 
its own advantages and disadvantages, the rapidity and 
facility of applying CRISPR/Cas systems for manipulating 
any genes in various types of cells and organisms makes 
it a novel and excellent genome engineering tool with 
an extraordinary performance (16,17)sequence-specific 
DNA-binding modules linked to a nonspecific DNA cleav-
age domain. ZFNs and TALENs enable a broad range of 
genetic modifications by inducing DNA double-strand 
breaks that stimulate error-prone nonhomologous end 
joining or homology-directed repair at specific genomic 
locations. Here, we review achievements made possible 
by site-specific nuclease technologies and discuss appli-
cations of these reagents for genetic analysis and manip-
ulation. In addition, we highlight the therapeutic poten-
tial of ZFNs and TALENs and discuss future prospects for 
the field, including the emergence of clustered regula-
tory interspaced short palindromic repeat (CRISPR.
The aim of the present study was to use bioinformatic 
tools to design single guide RNAs (sgRNAs) targeting the 
ABCB1 gene encoding Pgp, using the online DeskGen ref-
erence (https://www.deskgen.com), in order to knockout 
and inhibit the expression of the target gene. 
2. Methods
2.1 Study Design and Bioinformatics Tools
The transcript sequence of the ABCB1-202 gene with the 
ID number of ENST00000622132.4 was extracted from the 
Ensemble database. The free and easy to use https://www.
deskgen.com web site was used to design the knockout 
experiment considering the fact that the ultimate aim of 
this study was to knockout ABCB1 gene (Fig. 1.A). 
The name of the intended gene, which was ABCB1, was 
typed in the box appeared on the new page and Homo 
sapiens was chosen from the drop-down menu (Fig. 1.B). 
On the new page, maps of all the transcripts of the de-
sired gene, as in the Ensemble, were displayed in their 
original direction (Forward or Reverse). The promoter 
regions, the exons (including the protein coding regions 
and the 3UTR & 5UTR regions) as well as the stop codons 
were shown in distinct colours. To make it more conve-
nient, the intended variant number was selected from 
the relevant box and other variants became hidden for 
easier investigation of the exons of the target gene. The 
variant 202 was selected in the present study (Fig. 1.C). 
At this database, the spCas9 nuclease and 20 bp as the 
length of the sgRNA were set as the default. The nuclease 
can be changed using the “Option” toolbar and selecting 
“Set Nuclease”. 
The black circles on both forward and reverse sequenc-
es with different numbers represent the positions of the 
PAM regions and the corresponding strand, namely, the 
hybridation position with the sgRNA and it is, in fact, 
the cutting sites (Fig. 1.D). The numbers inside these cir-
cles indicate the on-target activity score of the desired 
sgRNA. This score predicts the activity of sgRNA and sub-
sequently the probability of cutting the double-strand 
DNA by the CRISPR nuclease. Through this scoring sys-
tem, it is possible to distinguish the powerful sgRNAs 
from weaker ones. The scoring range is from zero to 100. 
Therefore, it is ideal to select the sgRNAs with the high-
est score (closest to 100). In this database, sgRNAs with 
the scores higher than 60 are considered as to be in a 
good threshold for the proper functioning of the CRISPR 
system. However, if the sgRNA score out of this range, 
the threshold number can be reduced. Furthermore, it 
is possible to enhance the targeting efficiency by choos-
ing the preserved exons among all the variants of the in-
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tended gene. This can be useful for the complete knock-
out of the cells expressing multiple variants of a gene. In 
this study, all 28 exons of ABCB1 gene were separately ex-
amined in order to find the best regions containing the 
PAM sequence. Moreover, the threshold for appropriate 
sgRNA sequences was considered to be 50. By selecting 
each of the exons, separately, and choosing the desired 
threshold, the list of all the disposed sgRNA sequences 
in the intended exon is determined. The desired infor-
mation, including the exact location of the cutting site 
by nuclease, the GC content (ideally 30-70%) and the on-
target activity score are determined by selecting any 
of the sequences (Fig. 2. E). Afterward, by choosing the 
“Find off-targets” option, the off-target activity score of 
the selected sgRNA, as well as the information about the 
potential regions for off-target activity are illustrated 
(Fig. 1.F). Therefore, all the exons were individually se-
lected to find the regions containing PAM sequences, 
with a threshold over 50 and less off-target activity. The 
sites with a single base-pair mutation (1bp mismatches) 
or more than one off-target matches with a two base-
pair mutation (2bp mismatches) were discarded.
The next step was to send the list of all the regions con-
taining PAM sequences and the selected sgRNAs to the 
Chinese GeneCopoeia company for further analysis and 
selection of the most effective sgRNA. Finally, after com-
plementary analyzes using other algorithms, 3 sgRNA 
sequences were selected close to the start codon (ATG), 
in order to maximize the probability of knockout of the 
both exons, 4 and 5. The selected sgRNA sequences were 
then cloned into the intended plasmid along with the 
sequence of the Cas9 gene, promoter region, mCherry 
reporter gene and other required sequences. The final 
product was synthesized and delivered in lyophilized 
form by the GeneCopoeia Company.
2.2 Plasmid Propagation
According to the manufacturer’s instructions, the vec-
tors were dissolved in 300-400µl of deionized water and 
transformed into competent TOP10 cells using calcium 
chloride approach, mediated by thermal shock. Clones 
containing pCRISPR-CG01 vectors were cultured over-
night in a liquid LB culture medium supplemented with 
ampicillin, at 37 °C. Plasmid purification was performed 
using the GeNet Bio Plasmid Extraction Kit (GenetBioInc, 
Korea). 
2.3 Digestion Analysis
The extracted plasmid was electrophorised on 1% aga-
rose gel in order to confirm the success of the purifica-
tion process. To ensure the accuracy and integrity of the 
extracted plasmids, BamH1 and EcoR1 restriction enzymes 
were applied, using the common buffer Tango, to per-
form the enzymatic digestion at 37 ° C for 4 hours. Prod-
ucts of the digestion procedure were finally loaded on a 
1.5% agarose gel. 
3. Results
The steps of selecting the target gene for designing the 
appropriate sgRNAs are presented in Figure 1.
Figure 1. Example of outputs of the DeskGen Web site for identifying 
sgRNA target locations. A) Selecting type of the test (knockout). B) Select-
ing the intended gene and the organism. C) Selecting the variant of the 
gene: ABCB1 gene, variant 202. D) regions containing the PAM sequence 
and its corresponding strand, ie, the sgRNA hybridation site. E) On target 
activity analysis of the potential sgRNA sequences. F) Off-target activity 
analysis of the sgRNA sequences.
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The intended designed construct was provided by the 
Chinese GeneCopoeia company, cloned into the pCRISPR-
CG01 plasmid with a size of 10442 bp (Fig. 2). The sgRNAs 
target sequences (exons 4 and 5), along with the PAM re-
gion, are presented in Table 1.
Considering that the sites of action of the EcoR1 and BamH1 restriction enzymes were respectively located at 
base 10003 and 10335 of the plasmid sequence, results 
of electrophoresising digested pCRISPR-CG01 vector by 
BamH1 and EcoR1 enzymes loaded on a 1.5% agarose gel 
along with a 1 Kb DNA marker and detecting two bands, 
with approximate length of 330 bp and 10100 bp, con-
firmed the integrity of the plasmid and the digestion 
process (Fig. 3). Finally, concentration of the confirmed 
plasmids was determined in order to be used for trans-
fection of the ovarian epithelial cancer cells to target and 
knockout the ABCB1 gene which encode the Pgp mem-
brane transporter.
Figure 2.  Map of sgRNA clone. The selected sgRNA sequences were cloned into plasmid along with the sequence of the Cas9 gene, promoter region, 
mCherry reporter gene and other required sequences.
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Figure 3.  Enzymatic digestion of the pCRISPR- CG01 plasmid. Column 1: 1 
Kb DNA marker, Column 2: The pCRISPR GC01 plasmid digestion product 
with both the BamH1 and EcoR1 enzymes and detection of two bands of 
330 and 10100 bp.
4. Discussion 
Many human cancer cells express the ABCB1 gene at a 
level that leads to multi-drug resistance. In fact, based 
on the analysis of a wide range of cancers, about 50% of 
the human malignancies over-express ABCB1 gene dur-
ing the course of treatment, which reduces the impact 
of chemotherapy and defects the treatment outcomes. 
Therefore, targeting Pgp has led to the development of 
Pgp inhibitors that can inhibit the transmission of the 
substrate and lead to an increase in the intracellular 
accumulation of the drug (5,18). Over the past three de-
cades, a wide range of ABCB1 inhibitors have been de-
veloped; however, none of them have been approved 
for clinical use. The main disadvantages of these ABCB1 
inhibitors are nonspecific toxicity, as well as toxic inter-
actions between the inhibitor and the chemotherapy 
agents used to treat the patient (19,20). Nonetheless, ge-
netic tools are promising approaches to overcome drug 
resistance in cancer. In the context of silencing the gene 
expression after transcription, RNAi is recognized as a 
leading tool for targeted knockdown of the gene. How-
ever, transmission constraints, low stability on blood 
flow, unwanted and unpredictable off-target effects and 
ultimately stimulation of the immune system are the 
main limiting factors of RNAi in terms of therapeutic 
applications (16,21,22). The most recent genomic engi-
neering tools include protein domains (ZFN or TALE) 
that bind to specific regions on DNA and are able to 
manipulate the structure and function of the genome 
by integrating with a variety of effecter domains. These 
effecter domains include nucleases, transcriptional 
activators or repressors, recombinases, transposases, 
DNA and histone methyltransferases as well as histone 
acetyltransferases (16). ZF and TALE-based nucleases re-
quire detailed and distinct design for any genome site 
and are, in fact, known as custom-designed nucleases 
(CDNs). Therefore, their design is more pricey and time 
consuming compared to the most recent generation of 
genomic tools, CRISPR systems. The new CRISPR/Cas sys-
tem, as a potential effective alternative to the ZFN and 
TALEN tools, is able to induce targeted genetic changes. 
These sgRNA-based nucleases, in addition to being con-
venient, inexpensive and quickly designed, have shown 
more efficiency and flexibility than CDNs and are sig-
nificant potential subjects in the field of biological and 
medical studies (16,23). Fortunately, development of 
new CRISPR/Cas variants, as well as their ability to tar-
get multiple genetic locations simultaneously, makes 
achieving ultimate therapeutic goals with maximum 
efficiency possible (24). In addition to recent advances 
in generating more computational resources in the 
field of genome editing, the simultaneous application 
of other available “in silico” resources to study genome 
sequencing is recommended. These resources and al-
gorithms have the potential to provide new aspects of 
genomic editing tools in terms of bioinformatics de-
sign as well as post-genome editing analysis. Although 
the emergence of computational resources has been 
rapidly increasing in order to enhance the efficiency 
of genome editing tools, online resources and accurate 
computational algorithms are also required for post-
editing down-stream analysis as well as total genomic 
scanning (25).
4.1 Conclusion
In the present study, the sequences of all the 28 exons 
of the ABCB1 gene were investigated, using the DeskGen 
computational tool, in order to find the best target sites 
for the sgRNA. Finally, three sgRNAs, targeting exons 4 
and 5, were selected for complete suppression and knock-
out of Pgp expression in order to evaluate the potential 
reversibility of sensitivity to chemotherapy agents in a 
drug-resistant cancer cell line.
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